by Gonzalo Payan | Nov 4, 2019
MAX BioPharma, Inc. recently published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells. Oxy186 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562610/) and Oxy210 (https://www.mdpi.com/2073-4409/8/10/1297/pdf)...by Gonzalo Payan | Oct 22, 2019
MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Paper...by Gonzalo Payan | Jun 19, 2019
MAX BioPharma scientists publish new paper titled “Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties”. Paper available from https://www.mdpi.com/2073-4409/8/5/509...by Gonzalo Payan | Oct 22, 2018
MAX BioPharma is pleased to announce that it has been awarded a Phase IIB grant in continuation of the successful completion of our Phase II award to develop an effective compound for intervention in osteoporosis by stimulating bone formation in patients that have...by Gonzalo Payan | Sep 11, 2018
MAX BioPharma selected to present at the LA BioMed Innovation Showcase to be held on September 13th, 2018 in Manhattan Beach, California.